BSE Live
Apr 10, 16:01Prev. Close
339.75
Open Price
344.15
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 10, 15:59Prev. Close
340.60
Open Price
341.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of FDC (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 200.85 | 216.99 | 201.06 | 170.18 | 172.87 | |
| Net CashFlow From Operating Activities | 118.72 | 147.58 | 149.05 | 140.29 | 118.68 | |
| Net Cash Used In Investing Activities | -81.05 | -61.95 | -105.08 | -105.62 | -30.36 | |
| Net Cash Used From Financing Activities | -47.47 | -74.93 | -62.28 | -58.41 | -57.35 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -9.80 | 10.70 | -18.30 | -23.75 | 30.97 | |
| Cash And Cash Equivalents Begin of Year | 21.08 | 2.57 | 20.87 | 44.62 | 13.65 | |
| Cash And Cash Equivalents End Of Year | 11.28 | 13.27 | 2.57 | 20.87 | 44.62 |
10.02.2026
FDC Consolidated December 2025 Net Sales at Rs 464.71 crore, up 0.13% Y-o-Y
09.02.2026
FDC Standalone December 2025 Net Sales at Rs 457.94 crore, down 0.2% Y-o-Y
11.11.2025
FDC Standalone September 2025 Net Sales at Rs 461.74 crore, down 8.58% Y-o-Y
07.11.2025
FDC Consolidated September 2025 Net Sales at Rs 473.03 crore, down 7.94% Y-o-Y
10.02.2026
FDC Consolidated December 2025 Net Sales at Rs 464.71 crore, up 0.13% Y-o-Y
09.02.2026
FDC Standalone December 2025 Net Sales at Rs 457.94 crore, down 0.2% Y-o-Y
11.11.2025
FDC Standalone September 2025 Net Sales at Rs 461.74 crore, down 8.58% Y-o-Y
07.11.2025
FDC Consolidated September 2025 Net Sales at Rs 473.03 crore, down 7.94% Y-o-Y
10.04.2026
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth